Loading patent…
AssigneeLabaz
InventorsCharles Pigerol, Pierre Eymard, Jean-Claude Vernieres, Jean-Pierre Werbenec
Estimating the term…
Methylamine derivatives of the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.3 each represent a hydrogen atom or a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 1 to 6 carbon atoms, R.sub.2 represents a straight- or branched-chain alkyl, alkenyl or alkynyl radical containing from 2 to 7 carbon atoms with the proviso that when R.sub.2 represents an alkenyl radical of the formula CH.tbd.CH--R.sub.4 or an alkynyl radical of the formula C=C--R.sub.4, in which R.sub.4 represents a hydrogen atom or a straight- or branched-chain alkyl radical of 1 to 5 carbon atoms, R.sub.1 and R.sub.3 each represent an atom of hydrogen or an alkyl radical, R.sub.1, R.sub.2 and R.sub.3 being such that no compound of formula I possesses more than 13 carbon atoms. They are useful for treating Parkinson's disease and for correcting extra-pyramidal disturbances provoked by neuroleptics.
Method of treating Parkinson's disease and correcting extra-pyramidal disturbances provoked by neuroleptics comprising the administration to a subject in need of such treatment of an effective dose of at least one methylamine derivative of the formula:
Method for treating Parkinson's disease and correcting the extra-pyramidal disturbances provoked by the neuroleptics comprising the administration to a subject in need of such treatment of an effective dose of 1,1-di-n-propyl-n-butylamine or a pharmaceutically acceptable acid addition salt thereof.
A pharmaceutical or veterinary composition for use in the treatment of Parkinson's disease and for the correction of extra-pyramidal disturbances provoked by neuroleptics comprising as an essential active ingredient at least one methylamine derivative of the formula:
A pharmaceutical or veterinary composition for use in the treatment of Parkinson's disease and for the correction of extra-pyramidal disturbances provoked by neuroleptics comprising as an essential active ingredient 1,1-di-n-propyl-n-butylamine or a pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutical carrier or excipient therefor.
Dependencies are inferred from the claim text.